Dimerix Confirms Phase 3 FSGS Kidney Disease Stud Design Appropriate For China
Posted: 4 July 2023 Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical study in inflammatory disease, today confirmed that the Chinese regulatory agency, National Medical Products Administration (NMPA) has provided a written response on…
Neuren completes enrolment in Phelan-McDermid syndrome Phase 2 trial
Posted: 4 July 2023 Neuren Pharmaceuticals (ASX: NEU) today announced that enrolment of subjects into its Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome has now been completed. Topline results from the trial are expected to be…
Important Phase I Extension Clinical Study of AD-214 Approved
Posted: 30 June 2023 AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products from its i-body platform, is pleased to announce that it has received Human Research Ethics Committee (HREC) approval to commence a…
Neuren opens first site in US for Prader-Willi syndrome Phase 2 trial
Posted: 28 June 2023 Neuren Pharmaceuticals (ASX: NEU) today announced that the first site in the United States for its Phase 2 clinical trial of NNZ-2591 in Prader-Willi syndrome is now open. Neuren CEO Jon Pilcher commented “The…
Imagion expands collaboration with Siemens Healthineers to United States
Posted: 28 June 2023 Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce it has expanded its collaboration agreement with Siemens Healthineers. In addition to extending…
Immutep Completes A$80 Million Capital Raise
Posted: 28 June 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces the successful completion of an A$80 million capital raise to…
Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor
Posted: 28 June 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced the grant of a new patent (number 11,684,654) entitled “Combined Preparations for the Treatment of…
New national venture strengthens home-grown medicine outcomes
Posted: 28 June 2023 The Medical Research Future Fund (MRFF) has invested $9.75 million into establishing MedChem Australia, a new national medicinal chemistry initiative. At a glance MRFF National Critical Research Infrastructure Grant invests $9.75 million to establish…
Finding rewrites understanding into Parkinson’s disease pathway
Posted: 28 June 2023 Researchers have solved a long-standing mystery about how a protein helps rid the body of damaged mitochondria, in findings that could help lead to potential new treatments for Parkinson’s disease. At a glance Discovery…
Cumming Global Centre for Pandemic Therapeutics receives $5 million grant from The Ian Potter Foundation
Posted: 28 June 2023 The Cumming Global Centre for Pandemic Therapeutics (Cumming Global Centre) has received a generous $5 million seed grant from one of Australia’s leading philanthropic organisations, The Ian Potter Foundation. Launched in August 2022, the Doherty Institute’s Cumming…
Excellent Clinical Data For SubB2M/CA15-3 Breast Cancer Test
Posted: 27 July 2023 INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company), a developer of next-generation exosome solutions and precision diagnostics, is pleased to announce excellent results from an independent clinical validation study of its SubB2M/CA15-3 test for breast…
Immuron to go ahead with IMM-529 cGMP manufacturing and proceed with FDA pre-IND submission
Posted: 27 June 2023 The Board of Directors of Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has given the green light for the company to proceed with IMM-529 cGMP manufacturing for the treatment of a form of gastrointestinal disease. Directors have also approved…
